Image:Temozolomide.png
Find information on thousands of medical conditions and prescription drugs.

Temodar

more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Background

Temozolomide (brand name Temodar®) is an oral alkylating agent used for the treatment of refractory anaplastic astrocytoma -- a type of cancerous brain tumour. A derivative of imidazotetrazine, temozolomide is the prodrug of MTIC (3-methyl-(triazen-1-yl)imidazole-4-carboxamide). Temodar is marketed by Schering Corporation, which also markets other well-known prescription drugs such as Clarinex, Nasonex, Levitra, Cipro, Vytorin, Diprolene, Elocon and Lotrisone.

Indications

  • Glioblastoma multiforme: for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as manitenance treatment.
  • Anaplastic astrocytoma: for the treatment of adult patients with refractory anaplastic atrocytoma (ie. patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine).
  • Unlabeled uses: Metastatic melanoma.

Dosage Forms

Temozolomide is available in the United States in 5mg, 20mg, 100mg, & 250mg capsules.

Read more at Wikipedia.org


[List your site here Free!]


A Panoply Of Product Approvals
From FDA Consumer, 5/1/00 by Tamar Nordenberg

A new device that can improve blood flow to the heart by puncturing tiny therapeutic holes in places that traditional coronary artery bypass surgery can't reach is just one of more than 140 medical products approved by FDA last year.

In 1999, FDA approved a wide range of innovative health-care products to treat medical conditions both common and rare--from brain and breast cancer, HIV, heart disease, and diabetes to the little-known but potentially life-threatening genetic disorder called familial adenomatous polyposis.

The agency's Center for Drug Evaluation and Research approved 83 new drugs in a median FDA review time of just under 12 months overall and a little over six months for the 28 "priority" products deemed to represent a significant advance over existing treatment options. The Center for Biologics Evaluation and Research approved 24 products in a median time of just under 8.5 months. And the Center for Devices and Radiological Health approved 41 products in about a nine-month median total review time.

Among the drugs and devices approved were 20 drugs and biologics that qualify under the Orphan Drug Program, which grants special privileges and marketing incentives to makers of treatments for conditions affecting fewer than 200,000 patients, too few to be routinely profitable.

In addition, seven products were developed under the Humanitarian Device Exemption, which exempts manufacturers from conducting clinical trials in some cases in which a device's benefit is expected to a reach a U.S. patient population of fewer than 4,000.

The following chart lists some of the most important drugs and devices that FDA has OK'd for marketing in 1999--some for the first time and others for a new use--along with a general description of the condition for which each is newly approved.

DRUGS (INCLUDING BIOLOGICS)

COPYRIGHT 2000 U.S. Government Printing Office
COPYRIGHT 2004 Gale Group

Return to Temodar
Home Contact Resources Exchange Links ebay